Key Highlights
- Sono-Tek reported second quarter adjusted Earnings Per Share of USD 0.02, missing the USD 0.05 estimate.
- First half Revenue increased 6% to approximately USD 10.9 million, with gross Margin expanding to 55% from 51%.
- Medical market sales rose 289% in the first half to approximately USD 7.1 million.
- A new USD 7.2 million clean energy order marks the largest aggregate customer order in company history.
Sono-Tek Corporation (NASDAQ:SOTK) is a small cap manufacturer of precision ultrasonic coating systems serving medical device, microelectronics, industrial and alternative energy customers. The company has spent recent years investing in a forward deployed engineering team designed to help customers transition from Research and Development into higher Volume commercial manufacturing, a shift that can significantly raise the average selling price of its production systems.
This quarter's results reflected that transition in progress, with strong first half growth in the medical segment offset by a softer second quarter driven by the timing of large system shipments, even as the company's Backlog visibility improved substantially following quarter end across both its medical and alternative energy customer relationships.
Medical Strength Offset by Order Timing
First half revenue increased 6% to approximately USD 10.9 million, with gross margin expanding to 55% from 51% a year earlier and Operating Income rising 41% to approximately USD 1.28 million. However, second quarter revenue of USD 5.23 million and adjusted earnings per share of USD 0.02 missed the USD 5.54 million and USD 0.05 estimates, reflecting a step down from an unusually strong first quarter. Medical market sales rose 289% in the first half to approximately USD 7.1 million, driven by drug eluting balloon and stent coating demand.
Following quarter end, the company announced three new clean energy orders totaling approximately USD 7.2 million, representing the largest aggregate customer order in company history, which combined with a previously announced USD 3.6 million medical order to push total backlog above USD 10.7 million, with most of that volume expected to ship in fiscal 2028.
Backlog Growth Against Order Timing Risk
Management indicated that repeat orders from mature customers on high average selling price systems tend to carry better gross margins due to accumulated cost optimization, which could support profitability as the newly expanded backlog begins shipping. The company also outlined a phased Manufacturing capacity expansion intended to lift output capability from approximately USD 27 million to USD 44 million over time.
Risks include the inherent lumpiness of large system orders, which can cause meaningful quarter to quarter revenue and margin variability, as well as continued softness in the alternative energy segment tied to shifting government policy. Management reiterated guidance for flat to modest revenue growth in fiscal 2027, suggesting near term results may remain uneven ahead of the larger fiscal 2028 shipments.
Where Things Stand
Sono-Tek's first half results point to a company in transition, with medical market strength and a record clean energy order offsetting a softer second quarter tied to order timing. The company's Balance Sheet remains Debt free with a growing cash position, providing flexibility to fund capacity expansion ahead of expected fiscal 2028 shipments. Whether the backlog converts smoothly into revenue may depend on execution through a planned manufacturing expansion and continued Demand across its medical, industrial and emerging semiconductor related end markets.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...